InvestmentJun 22, 2026, 09:07 AM
InterCure Secures NIS 22M Private Placement Financing
AI Summary
InterCure Ltd. announced it has secured NIS 22 million (approximately US$7.4 million) in a private placement financing, with the potential to increase to NIS 54 million (approximately US$18.6 million) if warrants are fully exercised. The funding includes investments from the company's CEO and leading pharma-focused hedge funds. The proceeds are intended to support the recovery and expansion of its Nir Oz facility, meet growing demand in international markets, and accelerate global expansion, particularly in Germany and regulated U.S. medical cannabis markets.
Key Highlights
- Secured NIS 22 million (approximately US$7.4 million) in private placement financing.
- Funding may increase to NIS 54 million (approximately US$18.6 million) if warrants are fully exercised.
- Issued 7,895,143 ordinary shares at NIS 2.75 (US$0.94) per share.
- Issued warrants to purchase up to 7,895,143 additional shares at NIS 4.125 (US$1.41) per share.
- Share purchase price represents a premium over the NIS 2.69 closing price on June 17, 2026.
- Warrant exercise price represents an approximately 53% premium over the June 17, 2026 closing price.
- Funding includes commitments from CEO Alexander Rabinovich and leading pharma-focused hedge funds.
- Proceeds will support Nir Oz facility recovery, international expansion, and growth in Germany and US markets.
Price Impact
More from INCR